PMID- 31722710
OWN - NLM
STAT- MEDLINE
DCOM- 20200512
LR  - 20200512
IS  - 1476-7120 (Electronic)
IS  - 1476-7120 (Linking)
VI  - 17
IP  - 1
DP  - 2019 Nov 13
TI  - Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and 
      cardiovascular outcome: a systematic review.
PG  - 26
LID - 10.1186/s12947-019-0177-8 [doi]
LID - 26
AB  - A high incidence of left ventricular diastolic dysfunction and increased risk of 
      cardiovascular events have been reported in patients with diabetes mellitus. 
      Sodium glucose cotransporter 2 (SGLT2) inhibitors selectively inhibit kidney 
      glucose and sodium reabsorption, and cardiovascular benefits of SGLT2 inhibitors 
      beyond other antidiabetic drugs have been reported in type 2 diabetes mellitus 
      (T2DM) clinical trials. However, underlying mechanisms contributing to the 
      improvement of cardiovascular outcomes have not been clearly identified. In this 
      review, likely mechanisms of SGLT2 inhibitors contributing to a favorable 
      cardiovascular outcomes are discussed based on experimental and clinical studies 
      on cardiac function.
FAU - Matsumura, Koichiro
AU  - Matsumura K
AUID- ORCID: 0000-0002-9089-3505
AD  - Department of Cardiology, Kansai Medical University Medical Center, 10-15, 
      Fumizono-cho, Moriguchi, Osaka, 570-8507, Japan. kmatsumura1980@yahoo.co.jp.
FAU - Sugiura, Tetsuro
AU  - Sugiura T
AD  - Department of Cardiology, Kansai Medical University Medical Center, 10-15, 
      Fumizono-cho, Moriguchi, Osaka, 570-8507, Japan.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20191113
PL  - England
TA  - Cardiovasc Ultrasound
JT  - Cardiovascular ultrasound
JID - 101159952
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Animals
MH  - Cardiovascular Diseases/epidemiology/etiology/*physiopathology
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/physiopathology
MH  - Global Health
MH  - Humans
MH  - Incidence
MH  - Sodium-Glucose Transporter 2 Inhibitors/*pharmacology
MH  - Ventricular Function/*drug effects/physiology
PMC - PMC6854641
OTO - NOTNLM
OT  - Cardiac function
OT  - Diabetes mellitus
OT  - SGLT2 inhibitor
COIS- The authors declare that they have no competing interests.
EDAT- 2019/11/15 06:00
MHDA- 2020/05/13 06:00
PMCR- 2019/11/13
CRDT- 2019/11/15 06:00
PHST- 2019/09/26 00:00 [received]
PHST- 2019/11/06 00:00 [accepted]
PHST- 2019/11/15 06:00 [entrez]
PHST- 2019/11/15 06:00 [pubmed]
PHST- 2020/05/13 06:00 [medline]
PHST- 2019/11/13 00:00 [pmc-release]
AID - 10.1186/s12947-019-0177-8 [pii]
AID - 177 [pii]
AID - 10.1186/s12947-019-0177-8 [doi]
PST - epublish
SO  - Cardiovasc Ultrasound. 2019 Nov 13;17(1):26. doi: 10.1186/s12947-019-0177-8.